Chemokines in the cerebrospinal fluid of patients with active and stable relapsing-remitting multiple sclerosis

Brazilian Journal of Medical and Biological Research

Volumn 39, Issue 4, 2006, Pages 441-445

  Moreira, M A ^a   Souza, A L S ^a   Lana Peixoto, M A ^a   Teixeira, M M ^a   Teixeira, A L ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

CCL2; CXCL10; Inflammation; Leukocyte recruitment; Multiple sclerosis

Indexed keywords

ALPHA CHEMOKINE; BETA CHEMOKINE; BETA1A INTERFERON; CHEMOKINE; CYSTEINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES;

ADULT; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID LEVEL; CHRONIC INFLAMMATION; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEMYELINATING DISEASE; DISEASE ACTIVITY; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOPATHOGENESIS; LEUKOCYTE ACTIVATION; MALE; MONONUCLEAR CELL; MULTIPLE SCLEROSIS; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS;

EID: 33645824917     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2006000400003     Document Type: Article

References (24)

1. Lassmann H & Ransohoff RM (2004). The CD4-Th1 model for multiple sclerosis: a crucial re-appraisal. Trends in Immunology, 25: 132-137.
2. Hafler DA (2004). Multiple sclerosis. Journal of Clinical Investigation, 113: 788-794.
3. Kornek B & Lassmann H (2003). Neuropathology of multiple sclerosis. Brain Research Bulletin, 61: 321-326.
4. Noseworthy JH, Lucchinetti C, Rodriguez M et al. (2000). Multiple sclerosis. New England Journal of Medicine, 343: 938-952.
5. MacKay CR (2001). Chemokines: immunology's high impact factors. Nature Immunology, 2: 95-101.
6. Moser B, Wolf M, Walz A et al. (2004). Chemokines: multiple levels of leukocyte migration control. Trends in Immunology, 25: 75-84.
7. Trebst C & Ransohoff RM (2001). Investigating chemokines and chemokine receptors in patients with multiple sclerosis: opportunities and challenges. Archives of Neurology, 58: 1975-1980.
8. Ransohoff RM (2002). The chemokine system in neuroinflammation: an update. Journal of infectious Diseases, 186 (Suppl 2): S152-S156.
9. Sellebjerg F & Sorensen TL (2003). Chemokines and matrix metal-loproteinase-9 in leukocyte recruitment to the central nervous system. Brain Research Bulletin, 61: 347-355.
10. Sorensen TL, Tani M, Jensen J et al. (1999). Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. Journal of Clinical Investigation, 103: 807-815.
11. Lana-Peixoto MA, Frota E, Campos GB et al. (2002). The prevalence of multiple sclerosis in Belo Horizonte, Brazil. Multiple Sclerosis, 8 (Suppl 1): 38-39.
12. Poser CM, Paty DW, Scheinberg L et al. (1983). New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Annals of Neurology, 13: 227-231.
13. Franciotta D, Martino G, Zardini E et al. (2001). Serum and CSF levels of MCP-1 and IP-10 in multiple sclerosis patients with acute and stable disease and undergoing immunomodulatory therapies. Journal of Neuroimmunology, 115: 192-198.
14. Sindern E, Niederkinkhaus Y, Henschel M et al. (2001). Differential release of β-chemokines in serum and CSF of patients with relapsing-remitting multiple sclerosis. Acta Neurologica Scandinavica, 104: 88-91.
15. Mahad DJ, Howell SJ & Woodroofe MN (2002). Expression of chemokines in the CSF and correlation with clinical disease activity in patients with multiple sclerosis. Journal of Neurology, Neurosurgery, and Psychiatry, 72: 498-502.
16. Scarpini E, Galimberti D, Baron P et al. (2002). IP-10 and MCP-1 levels in CSF and serum from multiple sclerosis patients with different clinical subtypes of the disease. Journal of Neurological Sciences, 195: 41-46.
17. Narikawa K, Misu T, Fujihara K et al. (2004). CSF chemokine levels in relapsing neuromyelitis optica and multiple sclerosis. Journal of Neuroimmunology, 149:182-186.
18. Lana-Paixoto MA & Lana-Peixoto MI (1992). Is multiple sclerosis in Brazil and Asia alike? Arquivos de Neuropsiquiatria, 50: 119-125.
19. Arruda WO, Scola RH, Teive HA et al. (2001). Report on 200 cases from Curitiba, Southern Brazil and comparison with other Brazilian series. Arquivos de Neuropsiquiatria, 59: 165-170.
20. Mahad DJ & Ransohoff RM (2003). The role of MCP-1 (CCL2) and CCR2 in multiple sclerosis and experimental autoimmune encephalomyelitis (EAE). Seminars in Immunology, 15: 23-32.
21. Santos AC, Barsante MM, Arantes RM et al. (2005). CCL2 and CCL5 mediate leukocyte adhesion in experimental autoimmune encephalomyelitis: an intravital microscopy study. Journal of Neuroimmunology, 162:122-129.
22. Bartosik-Psujek H, Belniak E, Mitosek-Szewczyk K et al. (2004). Interleukin-8 and RANTES levels in patients with relapsing-remitting multiple sclerosis treated with cladribine. Acta Neurologica Scandinavica, 109: 390-392.
23. Bartosik-Psujek H & Stelmasiak Z (2005). The levels of chemokines CXCL8, CCL2 and CCL5 in multiple sclerosis patients are linked to the activity of the disease. European Journal of Neurology, 12: 49-54.
24. Bielekova B & Martin R (2004). Development of biomarkers in multiple sclerosis. Brain, 127: 1463-1478.